Swiss pharmaceutical company Novartis has dismissed criticism that it allegedly withheld information about animal testing data inaccuracies to United States authorities for a human gene therapy.
This content was published on
1 minute
swissinfo.ch/ug
NovartisExternal link said its subsidiary in California began investigating the alleged data manipulation for its gene therapy Zolgensma as soon as it learned about it. Once the company had interim conclusions, it shared the informationExternal link with the US Food and Drug Administration (FDA).
The agency said Novartis did not disclose the information about suspected data manipulation until after the $2.1 million (CHF2.1) therapy treatment for children under the age of two won approval by the US regulator in May.
In a statement, the pharma company explained that the data in question were a small portion of its overall submission and limited to an older process no longer in use.
“The assays in question were used for initial product testing and are nor currently used for commercial product release,” Novartis said.
According to the company, Zolgensma, the most expensive treatment ever, is safe, of high quality and effective in treating patients with spinal muscular atrophy.
The FDA has indicated that the drug will remain on the market. The company’s actions are being assessed and could lead to criminal or civil penalties if appropriate.
More
More
How can a drug cost $2.1 million?
This content was published on
US authorities have approved a $2.1 million gene therapy, making it the most expensive drug ever. Can such a price tag be justified?
Swiss President Karin Keller-Sutter makes official visit to Austria
This content was published on
Karin Keller-Sutter, who took over the rotating Swiss presidency this year, has made her first official visit abroad as president to Austria.
This content was published on
The boss of Swiss Post, Roberto Cirillo, is stepping down at the end of March after six years in the job, the company announced on Friday.
This content was published on
The name and logo of the former Credit Suisse headquarters at Paradeplatz 8 in Zurich's financial centre were officially replaced by those of UBS on Friday.
Outgoing Swiss federal police chief warns of insufficient resources
This content was published on
The outgoing director of the Federal Office of Police (Fedpol), Nicoletta della Valle, has warned that officers, prosecutors and investigators in Switzerland have insufficient resources to do their work.
Swiss university inaugurates Europe’s most powerful centrifuge
This content was published on
The federal technology institute ETH Zurich has inaugurated Europe's most powerful geotechnical centrifuge. Researchers use the instrument to simulate the effects of natural hazards.
Swiss film industry reports successful year in 2024
This content was published on
Swiss films did well in cinemas in 2024, recording over 907,000 admissions, the Federal Statistical Office (FSO) reports. They accounted for almost 9% of all films shown last year in Switzerland.
Glencore and Rio Tinto held talks on mining’s biggest-ever potential merger, say reports
This content was published on
The Swiss-based mining and commodities group Glencore and the British company Rio Tinto reportedly held early-stage talks last year about combining their businesses.
First municipalities begin Swiss-wide plastic packaging recycling scheme
This content was published on
A new collection system to recycle plastic packaging and drinks cartons has begun in a handful of Swiss municipalities - others should follow in the coming weeks.
This content was published on
Despite an ongoing restructuring programme, Swiss retail giant Migros continued to grow last year by 1.6%, posting record sales of CHF32.5 billion ($35.7 billion).
Swiss researchers warn ‘mega-droughts’ are spreading around the world
This content was published on
"Mega-droughts" are increasing worldwide - becoming more frequent, hotter and more widespread over the past 40 years, a study published on Thursday shows.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Pharma company Sandoz named in US price-fixing lawsuit
This content was published on
The Germany-based subsidiary of Novartis is targeted in a 44-state class action suit for breaching rules on fair competition.
This content was published on
Swiss pharmaceutical Novartis must face a US government lawsuit accusing it of paying millions of dollars in kickbacks to doctors.
This content was published on
Pressure groups Public Eye and Médecins du Monde have filed their objection to the European patent office in Munich. They claim that Kymriah was not invented by Novartis because the research behind the drug was carried out by public institutions. The medicament, which is used to treat leukaemia and lymph gland cancer on patients who have…
Novartis faces questions about proxy voting independence
This content was published on
Proxy votes submitted by shareholders ended up at Novartis headquarters instead of the elected representative ahead of the annual general meeting.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.